



To meet global targets to end tuberculosis, the world needs new and effective TB vaccines. Fortunately, several promising adult and adolescent TB vaccine candidates are in late-stage clinical trials. But vaccines can only save lives and prevent transmission if they are widely used, making preparation for the rollout of a TB vaccine program critical for adults and adolescents in affected countries.

GOALS

SMART4TB will complement the clinical development of new TB vaccines through a multi-pronged effort: synthesizing lessons from past adult and adolescent vaccine rollouts, partnering with countries and affected communities to gather data and help support readiness challenges, and leading global advocacy and coordination efforts, including the development of a TB vaccine preparedness repository and co-convening TB Vax Arm, a global coalition of civil society and community partners advocating for new TB vaccines.

KEY QUESTIONS



Who will need and benefit most from a new TB vaccine?



What barriers might prevent individuals from accessing and getting the vaccine, and how can these barriers be overcome?



Are local and national health systems ready for a new TB vaccine, and what preparations are needed?



How can various implementation strategies influence the use, acceptance, affordability, and impact of a new TB vaccine?

TEAM LEADERS

Rupali Limaye

Johns Hopkins University

Andrew Kerkhoff

University of California, San Francisco

Mike Frick

Treatment Action Group




Michelle Gill

Elizabeth Glaser Pediatric AIDS Foundation

Joeri S. Buis

KNCV Tuberculosis Foundation

FRAMEWORK

STEP 1 Gather Information	STEP 2 Co-create Solutions
 <p>Surveys, Interviews, and Other Research Methods to assess knowledge, attitudes, beliefs, intentions, and barriers to uptake of TB vaccines</p> <ul style="list-style-type: none"> households that have experienced TB households that have not experienced TB healthcare workers advocacy groups policy makers 	 <p>SMART4TB will partner closely with diverse stakeholders in each country to share data and co-create solutions for the most pressing challenges facing the country, which could include activities such as:</p> <ul style="list-style-type: none"> developing proactive communication strategies to combat misinformation, crafting a vaccine demand strategy, or supporting health systems with a tailored implementation and delivery plan.
 <p>Local and National Health System Readiness Assessments</p>	

In collaboration with local partners in USAID priority countries, starting with **Kenya and South Africa**, the SMART4TB team is implementing a two-step research process focused on community demand and acceptance, and health facility and system readiness for the successful rollout of an adult and adolescent TB vaccine.

About SMART4TB

The SMART4TB Consortium brings together experts in TB tools development, implementation science, capacity strengthening, civil society engagement and policy translation. Led by Johns Hopkins University, consortium members include the University of California, San Francisco; the Elizabeth Glaser Pediatric AIDS Foundation; KNCV Tuberculosis Foundation; Treatment Action Group; and local community and research partners.

This summary is made possible by the support of the American people through the United States Agency for International Development (USAID). The contents are the sole responsibility of SMART4TB and do not necessarily reflect the views of USAID or the United States Government or consortium collaborators or members. If you have any questions, please contact us at: smart4tbinfo@jh.edu.